Thiamet G mediates neuroprotection in experimental stroke by modulating microglia/macrophage polarization and inhibiting NF-κB p65 signaling

J Cereb Blood Flow Metab. 2017 Aug;37(8):2938-2951. doi: 10.1177/0271678X16679671. Epub 2016 Jan 1.


Inflammatory responses are accountable for secondary injury induced by acute ischemic stroke (AIS). Previous studies indicated that O-GlcNAc modification (O-GlcNAcylation) is involved in the pathology of AIS, and increase of O-GlcNAcylation by glucosamine attenuated the brain damage after ischemia/reperfusion. Inhibition of β-N-acetylglucosaminidase (OGA) with thiamet G (TMG) is an alternative option for accumulating O-GlcNAcylated proteins. In this study, we investigate the neuroprotective effect of TMG in a mouse model of experimental stroke. Our results indicate that TMG administration either before or after middle cerebral artery occlusion (MCAO) surgery dramatically reduced infarct volume compared with that in untreated controls. TMG treatment ameliorated the neurological deficits and improved clinical outcomes in neurobehavioral tests by modulating the expression of pro-inflammatory and anti-inflammatory cytokines. Additionally, TMG administration reduced the number of Iba1+ cells in MCAO mice, decreased expression of the M1 markers, and increased expression of the M2 markers in vivo. In vitro, M1 polarization of BV2 cells was inhibited by TMG treatment. Moreover, TMG decreased the expression of iNOS and COX2 mainly by suppressing NF-κB p65 signaling. These results suggest that TMG exerts a neuroprotective effect and could be useful as an anti-inflammatory agent for ischemic stroke therapy.

Keywords: Inflammation; macrophages; microglia; stroke; thiamet G.

MeSH terms

  • Acetylglucosamine / metabolism
  • Acetylglucosaminidase / antagonists & inhibitors
  • Animals
  • Biomarkers / metabolism
  • Disease Models, Animal
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Macrophages / pathology
  • Male
  • Mice, Inbred C57BL
  • Microglia / drug effects*
  • Microglia / metabolism
  • Microglia / pathology
  • N-Acetylglucosaminyltransferases / metabolism
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Pyrans / administration & dosage
  • Pyrans / therapeutic use*
  • Signal Transduction / drug effects
  • Stroke / drug therapy*
  • Stroke / metabolism
  • Stroke / pathology
  • Thiazoles / administration & dosage
  • Thiazoles / therapeutic use*
  • Transcription Factor RelA / metabolism*


  • Biomarkers
  • Neuroprotective Agents
  • Pyrans
  • Rela protein, mouse
  • Thiazoles
  • Transcription Factor RelA
  • thiamet G
  • N-Acetylglucosaminyltransferases
  • UDP-N-acetylglucosamine-peptide beta-N-acetylglucosaminyltransferase
  • Acetylglucosaminidase
  • Acetylglucosamine